Horizon Discovery Wins Most Promising Company at World Conference on Personalized Medicine

  • Email
  • Print

Award based on technology, performance to date, and forward plans

Cambridge and London, UK, 11 February 2013: Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has been named ŒMost Promising Company¹ at the Personalized Medicine World Conference 2013. Horizon was chosen from 32 shortlisted companies based on technology, historical performance of the company, and forward business plans.

The award was decided on a vote by a panel of pharma executives, healthcare professionals and US venture capitalists (60%) combined with votes from delegates attending the conference (40%). Horizon was named the winner in each voting demographic.

Horizon's proprietary technology, GENESIS , is the most precise and flexible genome editing technology available. Using GENESIS, any endogenous gene sequence of a human or mammalian cell line can be altered quickly, reliably and without off-target effects. Horizon has applied GENESIS to create over 500 X-MAN isogenic cell lines, the world¹s first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These Œpatients-in-a-test-tube¹ are being used by academic and industry leaders (as well as Horizon itself in internal drug discovery programs) to identify the effect of individual genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

GENESIS and X-MAN derived products and services are also finding wide industrial application in bio-pharmaceutical process optimization, clinical diagnostic development, and the provision of reference standards for genomic based clinical research platforms.

Horizon's CEO, Dr Darrin Disley, commented: "This award is a testament to the strength of the Horizon team, and comes in recognition of what we have already achieved and what we are working towards - making a difference in the lives of cancer sufferers. The award also shows how competitive a UK based biotech company can be with its US and global counterparts. I look forward to leading Horizon in the next stages of the company¹s development."

According to Tal Behar, co-founder of PMWC:

"Personalized medicine is one of the most revolutionary accomplishments mankind has ever seen. Companies highlighted during this year's competition are at the forefront of this achievement and help solve the most pressing healthcare challenges of our time."

The award process was moderated by Melinda Richter, Founder and CEO, Prescience International: "We are very pleased and honored to be involved in an award that features such promising scientific breakthroughs from around the world," said Richter. "This year again, the quality of the award competitors demonstrates how much personalized medicine continues to grow."

About Horizon Discovery (http://www.horizondiscovery.com/)

Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company¹s proprietary rAAV gene-editing technology, GENESIS , is industry leading. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.

Horizon has applied GENESIS to create over 500 X-MAN cell lines, the world's first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These Œpatients-in-a-test-tube¹ are being used by academic and industry leaders to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the Œright drugs' for the Œright patients' based upon the unique genetic mutations that define their disease.

In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial applications in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms.

GENESIS and X-MAN are registered trademarks of Horizon Discovery Limited.

Contacts at Horizon:
Dr Darrin M Disley
CEO
Tel: +44 (0)
1223 655 587
Email: d.disley@horizondiscovery.com

  • <<
  • >>